TRANSITIONING TO VALUE-BASED CARE?
Biosimilars may help bridge the transition from fee-for-service to value-based care
BIOSIMILARS AND VALUE-BASED CARE MODELS IN ONCOLOGY
Links to sites outside of Pfizer are provided as a resource to the viewer. Pfizer accepts no responsibility for the content of linked sites.
The information provided in this website is intended only for healthcare professionals in the United States. The products discussed may have different product labeling in different countries.
